Novo nordisk a/s: eco 2025 - novo nordisk semaglutide data shows new health benefits across serious chronic diseases

BagsvÆrd, denmark, 6 may 2025 – novo nordisk today announced that new data spanning the company's industry-leading portfolio across metabolic and cardiovascular health will be presented at the upcoming 32nd european congress on obesity (eco), 11–14 may 2025. the data will further extend the wide-ranging evidence base for semaglutide through real-world evidence studies and additional analysis of the landmark cardiovascular outcomes trial, select, as well as part 1 of the phase 3 essence trial in metabolic dysfunction-associated steatohepatitis (mash). data will also be presented on the wider societal impacts of treating and preventing obesity, alongside analysis of the burden of obesity in adolescents.
ECO Ratings Summary
ECO Quant Ranking